Form 4: Amneal Pharmaceuticals Director Ted C. Nark Reports Stock Unit Vesting

Director Ted C. Nark of Amneal Pharmaceuticals reports the vesting of 76,453 restricted stock units, resulting in ownership of 300,771 Class A Common Stock shares.

Summary

• On May 10, 2024, Ted C. Nark, a director of Amneal Pharmaceuticals, Inc., had 76,453 restricted stock units vest.
• These units converted into Class A Common Stock.
• Following this transaction, Nark directly owns 300,771 shares of Class A Common Stock.
• The restricted stock units were initially granted on May 9, 2023, and vested on May 10, 2024.

Sentiment

Score: 5

Explanation: This is a routine disclosure of stock unit vesting, neither particularly positive nor negative.

Positives

• The vesting of restricted stock units aligns the director's interests with those of the shareholders.

Industry Context

This is a standard SEC Form 4 filing, reflecting changes in beneficial ownership by a company insider. Such filings are common and provide transparency to the market regarding insider transactions.

Stakeholder Impact

• The vesting of stock units aligns the director's interests with those of the shareholders, potentially encouraging decisions that benefit the company's long-term value.

Key Dates